Allergan

Global Botulinum Toxin In Urology Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 4, 2024
Health, Pharmaceutical, Overactive bladder, Conference, Constipation, Cauda equina syndrome, Woman, Abdominal trauma, Government, Prevalence, Hospital, Urinary incontinence, Incidence, Stroke, Nerve, USD, Allergan, AbbVie, Abstract, Sphincter, Growth, Census

The "Botulinum Toxin In Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Botulinum Toxin In Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global botulinum toxin in urology market size is anticipated to reach USD 1.45 billion by 2030.
  • As a result, the rising geriatric population has led to an increase in urinary condition problems, further leading to market growth.
  • The region's robust healthcare infrastructure, skilled healthcare professionals, and advanced medical facilities contribute to the market growth in the region.

Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives

Retrieved on: 
Wednesday, January 3, 2024
Yee, Citadel, Accounting, Warner–Lambert, Invention, Mercer University, Sale, CFO, Acquisition, Marketing, Stephanie, Nobel Biocare, University, Parke Davis, Allergan, Inphi Corporation, Syneron Medical, GSK plc, Biologics license application, Patient, Pharmaceutical industry

IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.

Key Points: 
  • IRVINE, Calif., Jan. 3, 2024 /PRNewswire/ -- Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. ( www.luvantas.com ) as its wholly-owned North American subsidiary.
  • More information on this state-of-the-art formulation of Botulinum toxin will be provided once regulatory approvals are obtained.
  • In connection with the formation of Luvantas, Thomas A. Albright has been appointed its President and CEO and Stephanie A. Yee has been appointed its CFO.
  • As CEO, Tom brings 40 years of healthcare experience to Luvantas with medical aesthetic leadership roles since 2000.

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, December 12, 2023
Marketing, Alimera Sciences, Dermatology, Uveitis, Physician, Weight loss, Optometry, Injection, Recurrence, Allergan, Genomics, Patient, Grand Valley State University, Compensated emancipation, Employment, AbbVie, Pharmaceutical industry

Sales, Eye Care, Area Director, Facial Aesthetics and Senior Product Manager, Lumigan (glaucoma product).

Key Points: 
  • Sales, Eye Care, Area Director, Facial Aesthetics and Senior Product Manager, Lumigan (glaucoma product).
  • He most recently served as Chief Commercial Officer at Dermtech International, a leading genomics company in dermatology.
  • in business administration from Grand Valley State University, Allendale, Mich.
    “I’m looking forward to building upon Alimera’s strong foundation to establish a program for long-term success,” said Mr. Wood.
  • The Inducement Option is an inducement material to Mr. Wood entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights

Retrieved on: 
Thursday, November 9, 2023
Drug development, Three Months, Ophthalmology, Safety, Annual general meeting, Research, American Academy of Ophthalmology, Gene, Allergan, Investment, Anti-VEGF, American Academy, Data, Patient, Cell, LUNA, OPTIC, AAO, AMD, NHP, CMC, Injection, CST, Inflammation, Pharmaceutical industry, Dietary supplement, Medical imaging, Medical device, Cryptocurrency, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • “In our OPTIC presentation at AAO, we’ve built upon our industry leading dataset in wet AMD gene therapy,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • Scientific Meeting Presentations: In October 2023, Adverum showcased non-clinical data in two presentations at the European Society of Cell and Gene Therapy 2023 Annual Meeting.
  • Stock-based compensation expense included in research and development expenses was $1.2 million for the third quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.2 million for the third quarter of 2023.

Lecheng, MSD vow to deepen medical cooperation

Retrieved on: 
Friday, November 10, 2023
MSD, Sale, Research, Intuitive Surgical, Boston Scientific, Grifols, Sanofi, Roche, Patient, Multimedia, China International Import Expo, AbbVie, Friends, FANCL, Novartis, Lecheng, Amgen, Fine chemical, Generic drug, Pfizer, Allergan, Cordis, Bayer

The Lecheng delegation visited the booths of "new friends" such as Grifols, Chiesi, FANCL, and Cordis, and engaged in discussions and exchanges to establish a solid foundation for future cooperation.

Key Points: 
  • The Lecheng delegation visited the booths of "new friends" such as Grifols, Chiesi, FANCL, and Cordis, and engaged in discussions and exchanges to establish a solid foundation for future cooperation.
  • They also deepened their cooperation with "old friends" like Novartis, MSD, Sanofi, AbbVie, Bayer, Roche, Lilly, Johnson & Johnson, Amgen, Carl Zeiss, Gilead, Pfizer, Boston Scientific, Roche Diagnostics, Intuitive Surgical, and Allergan.
  • It was at this year's expo that MSD launched its MSD (Hainan) Innovative Medical Co Ltd, on November 6.
  • MSD, headquartered in New Jersey, the United States, is a leading global pharmaceutical company with a focus on research, development and the sale of innovative medical products.

Cerba HealthCare Changes Its Governance and Appoints Emmanuel Ligner Group Chief Executive Officer

Retrieved on: 
Thursday, November 9, 2023
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Otsuka Pharmaceutical, Abbott, Iveco, Exor, History, Leo Pharma, Pathology, Zodiac Aerospace, HTL, CGG, Development, Procter & Gamble, Commercialization, GE, Supervisory board, Procter, Senior advisor, ICON PLC, Stellantis, Pharmaceutical industry, Management, Allergan, Thales of Miletus

Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.

Key Points: 
  • Cerba HealthCare, a leading player in medical diagnostics, announces the appointment of Emmanuel Ligner as Chief Executive Officer of the Group.
  • Cerba HealthCare aims to remain at the forefront of medical innovation to help develop new treatments and improve patient health.
  • Emmanuel Ligner, Group Chief Executive Officer, said: « Cerba HealthCare is a leading company in the field of medical diagnostics as evidenced by the Group’s growth and the importance it has placed on innovation since its very inception.
  • »
    Jérôme Thill, Senior Advisor and former Chief Executive Officer of the Group, adds: « As I step down as Chief Executive Officer, I would like to thank all of Cerba HealthCare’s teams and partners.

Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors

Retrieved on: 
Monday, November 6, 2023
Actinium, Therapy, Ophthalmology, Organon, AMD, Merck, Acquisition, Schering-Plough, Research, Drug development, Bayer, University, Schizophrenia, Pembrolizumab, Knowledge management, AbbVie, Depression, University of Wales, Newport, Patient, Mirtazapine, Pharmaceutical industry, Volastra, Bimatoprost, Adverum Biotechnologies, Allergan

"We are excited to welcome David to Adverum’s Board of Directors.

Key Points: 
  • "We are excited to welcome David to Adverum’s Board of Directors.
  • He brings an exceptional breadth of experience and a track record of success in pharmaceutical R&D and has launched multiple transformative products throughout his career, notably in ophthalmology," stated Patrick Machado, J.D., board chair of Adverum Biotechnologies.
  • “On behalf of the management team at Adverum, I’d like to extend a warm welcome to David,” added Laurent Fischer, M.D., president and chief executive officer of Adverum.
  • from the University of Manchester and his Ph.D. from the University of Wales.

Lexicon Strengthens Management Team With Two New Executives

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, National Investor Relations Institute, Professional corporation, Bristol Myers Squibb, Melinta Therapeutics, Policy, AbbVie, Lexicon, Therapy, Ophthalmology, Actavis, Intercept, BS, Seton Hall University, Ozanimod, University, Amarin, Warner Chilcott, MBA, Ladenburg Thalmann, Alemtuzumab, Allergan, Business administration, Marketing, Wall Street, Watson Labs, Villalba v Merrill Lynch & Co Inc, Sclerosis, Heart failure, Intercept Pharmaceuticals, Pharmaceutical industry

THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Matthew Cullen is joining the company as vice president of value and access, effective November 1, 2023, and Lisa DeFrancesco will join as head of investor relations and corporate strategy, effective November 13, 2023.

Key Points: 
  • Mr. Cullen brings Lexicon more than 35 years of industry experience in market access and sales leadership.
  • Before joining Lexicon, Matt served as vice president, value, access and policy at Apellis Pharmaceuticals where he led the market access launch of rare disease drug EMPAVELI® (pegcetacoplan) and ophthalmology drug SYFOVRE® (pegcetacoplan injection).
  • His responsibilities included pricing and contracting, payer strategy and marketing, corporate and strategic account management, field reimbursement, trade and distribution, and training.
  • Prior to Apellis, Mr. Cullen led strategic payer marketing and access teams at Bristol-Myers Squibb for ELIQUIS® (apixaban) and ORENCIA® (abatacept).

Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
Science, Other Science, General Health, Health, Medical Devices, Data Management, Technology, Mobile, Wireless, GE HealthCare, GE Ventures, Laboratory, Conditional sentence, Oak Investment Partners, Doctor of Philosophy, Multimedia, M&A, Patient, Mayo Collaborative Services v. Prometheus Laboratories, Inc., Management, Allergan

Aptatek BioSciences, Inc. , a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.

Key Points: 
  • Aptatek BioSciences, Inc. , a developer of pioneering home monitoring tools for chronic disease patients, has appointed Drawbridge Health Chairperson Lee McCracken as a non-executive director.
  • He joins Ali Tinazli, PhD, CEO of Lifespin Health, as part of the growing team of highly experienced industry professionals on Aptatek’s board of directors.
  • Lee is Chairperson of Drawbridge Health, where he was previously recruited as CEO by GE Ventures and GE Healthcare.
  • For more information about Aptatek BioSciences and its innovative home monitoring solutions, please visit Aptatek BioSciences, Inc.

Medical Spa Expert Sei Tu Bella Aesthetics Joins Exclusive Haute Beauty Network

Retrieved on: 
Tuesday, October 31, 2023
Management of hair loss, Urogynecology, Rejuvenation, Gold, APRN, Tampa General Hospital, Education, Beauty, Life, Family, FACOG, MD, Empower, Abdomen, Day, Entrepreneurship, Dream, Elective surgery, Travel, Woman, Regenerative medicine, Merlo, Safety, Urinary incontinence, Emergency medicine, Morpheus, Nursing, Galderma, Allergan, Sculptra

NEW YORK, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Heather Merlo, APRN, FNP-C, is a board-certified family nurse practitioner, serving over 15 years in acute care and emergency medicine at Tampa General Hospital, a level 1 trauma center in Tampa, Florida. At seven months pregnant and facing the wall of the pandemic in 2021, Merlo embarked on the transition from corporate world America to women entrepreneurship. Fueled by the desire to balance the life of a Mother and her role as a women entrepreneur, increasing the confidence in women and striving for regenerative medicine and achieving optimal wellness, especially in light of the pandemic, Sei Tu Bella Aesthetics was founded. With no backup plan, Merlo turned her dreams into reality to pursue her love of aesthetic medicine and empower women by providing an emphasis on women's wellness services.

Key Points: 
  • Sei Tu Bella Aesthetics joins Haute Beauty Network as a medical spa expert representing the Tampa, FL market.
  • Prior to becoming an independent practitioner, she received specialized training in medical aesthetics at AMET and the top leaders in the industry, such as Merz Pharmaceuticals, Galderma, Allergan, Crown Aesthetics, Revive, and Inmode.
  • As the first Nurse Practitioner-owned MedSpa in the state of Florida to feature the Empower RF platform by Inmode, Sei Tu Bella Aesthetics became Lutz's premiere women's wellness institute.
  • Learn more about Sei Tu Bella Aesthetics by visiting: https://hauteliving.com/hautebeauty/member/sei-tu-bella-aesthetics/